

**Notice of References Cited**Application/Control No.  
09/532,001Applicant(s)/Patent Under  
Reexamination  
GOODWIN ET AL.Examiner  
Thomas G. Larson, Ph.D.Art Unit  
1635

Page 1 of 2

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US- -			
	B	US- -			
	C	US- -			
	D	US- -			
	E	US- -			
	F	US- -			
	G	US- -			
	H	US- -			
	I	US- -			
	J	US- -			
	K	US- -			
	L	US- -			
	M	US- -			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	- -				
	O	- -				
	P	- -				
	Q	- -				
	R	- -				
	S	- -				
	T	- -				

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Antisense '97: A roundtable on the state of the industry. Nature Biotechnol. 15 (1997): 519-524.
	V	Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93 (1996): 3161-3163.
	W	Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies. Stem Cells 18 (2000): 307-319.
	X	Khachigian et al. Nuclear factor -kB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J. Clinical Invest. (Aug, 1995) 96 (2): 1169-1175.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

Application/Control No.

09/532,001

Applicant(s)/Patent Under  
Reexamination  
GOODWIN ET AL.

Examiner

Thomas G. Larson, Ph.D.

Art Unit

1635

Page 2 of 2

**U.S. PATENT DOCUMENTS**

*		Document Number		Date	Name	Classification	
		Country Code-Number-Kind Code		MM-YYYY			
	A	US-	-				
	B	US-	-				
	C	US-	-				
	D	US-	-				
	E	US-	-				
	F	US-	-				
	G	US-	-				
	H	US-	-				
	I	US-	-				
	J	US-	-				
	K	US-	-				
	L	US-	-				
	M	US-	-				

**FOREIGN PATENT DOCUMENTS**

*		Document Number		Date	Country	Name	Classification	
		Country Code-Number-Kind Code		MM-YYYY				
	N	-	-					
	O	-	-					
	P	-	-					
	Q	-	-					
	R	-	-					
	S	-	-					
	T	-	-					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug Delivery Rev. 18(1996): 115-131.
	V	Stull et al. Antigene, ribozyme, and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12(1995): 465-483.
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.